We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+34.16%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$913M
AUM Growth
+$115M
Cap. Flow
-$67.2M
Cap. Flow %
-7.37%
Top 10 Hldgs %
28.56%
Holding
108
New
15
Increased
30
Reduced
36
Closed
14

Top Buys

Rank Stock Value
1
GH icon
Guardant Health
GH
+$8.67M
2
AXNX
Axonics, Inc. Common Stock
AXNX
+$7.88M
3
ISRG icon
Intuitive Surgical
ISRG
+$6.74M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$6.19M
5
LIVN icon
LivaNova
LIVN
+$6.07M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$11.5M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$11.3M
3
TMO icon
Thermo Fisher Scientific
TMO
+$11.1M
4
COR icon
Cencora
COR
+$8.15M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$7.67M

Sector Composition

Rank Sector Weight
1 Healthcare 93.54%
2 Financials 0.09%
3 Energy 0.09%
4 Technology 0.09%
5 Communication Services 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
51
Alkermes
ALKS
$8.25B
$7.55M 0.83%
370,000
+150,000
+68% +$2.98M
ADVM
52
DELISTED
Adverum Biotechnologies
ADVM
$7.49M 0.82%
65,000
+53,033
+443% +$4.67M
ISRG icon
53
Intuitive Surgical
ISRG
$134B
$7.09M 0.78%
+36,000
New +$6.74M
ALNY icon
54
Alnylam Pharmaceuticals
ALNY
$29.3B
$6.99M 0.77%
60,715
-8,285
-12% -$826K
GTHX
55
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.96M 0.76%
263,400
-272,257
-51% -$6.37M
BHVN
56
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$6.8M 0.75%
+125,000
New +$6.19M
COO icon
57
Cooper Companies
COO
$14.5B
$6.43M 0.7%
+80,000
New +$6.03M
DVAX
58
DELISTED
Dynavax Technologies
DVAX
$6.18M 0.68%
1,080,000
-154,335
-13% -$825K
BIIB icon
59
Biogen
BIIB
$30.7B
$5.93M 0.65%
+20,000
New +$5.55M
SGMO
60
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.86M 0.64%
700,000
-34,811
-5% -$320K
INCY icon
61
Incyte
INCY
$24.4B
$5.68M 0.62%
+65,000
New +$5.55M
XLRN
62
DELISTED
Acceleron Pharma
XLRN
$5.3M 0.58%
100,000
+30,000
+43% +$1.37M
AIMT
63
DELISTED
Aimmune Therapeutics
AIMT
$5.02M 0.55%
150,000
+799
+0.5% +$22.3K
BLUE
64
DELISTED
bluebird bio
BLUE
$5M 0.55%
4,400
+386
+10% +$420K
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$4.96M 0.54%
40,000
-7,600
-16% -$680K
QURE icon
66
uniQure
QURE
$3.22B
$4.3M 0.47%
+60,000
New +$3.29M
RIGL icon
67
Rigel Pharmaceuticals
RIGL
$750M
$4.07M 0.45%
190,000
-10,000
-5% -$206K
RVNC
68
DELISTED
Revance Therapeutics, Inc.
RVNC
$4.06M 0.44%
250,000
+76,083
+44% +$1.18M
NSTG
69
DELISTED
NanoString Technologies, Inc.
NSTG
$3.9M 0.43%
140,000
-2,126
-1% -$51.6K
MGTX icon
70
MeiraGTx Holdings
MGTX
$1.21B
$3.83M 0.42%
+191,300
New +$3.27M
SAGE
71
DELISTED
Sage Therapeutics
SAGE
$3.61M 0.4%
50,000
+30,000
+150% +$3.69M
MNTA
72
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.51M 0.39%
+178,073
New +$2.85M
RDUS
73
DELISTED
Radius Health, Inc.
RDUS
$3.43M 0.38%
170,000
+20,000
+13% +$486K
ONC
74
BeOne Medicines Ltd
ONC
$39.4B
$3.31M 0.36%
+20,000
New +$3.32M
ABEO icon
75
Abeona Therapeutics
ABEO
$413M
$3.27M 0.36%
40,000
– –
1 2
3
4 5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Rhenman & Partners Asset Management held 108 positions worth $913M, up 14% from $798M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $67.2M in Q4 2019, closing 14 positions and reducing 36 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials and Energy.

Against the trend, Rhenman & Partners Asset Management opened a new position in Axonics, Inc. Common Stock worth $9.14M.

  • Rhenman & Partners Asset Management's largest Q4 2019 buy was Axonics, Inc. Common Stock: 330,000 shares worth $9.14M.
  • Rhenman & Partners Asset Management added most to Guardant Health in Q4 2019, an estimated $8.67M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2019 reduction was CVS Health, cutting an estimated $11.5M.
  • Rhenman & Partners Asset Management fully exited Thermo Fisher Scientific in Q4 2019, selling an estimated $11.1M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $913M portfolio in Q4 2019.
  • Rhenman & Partners Asset Management opened 15 new positions and closed 14 in Q4 2019.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $913M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2019, filed 17 Jan 2020.